Literature DB >> 24574779

Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates.

Seung Bae Yoon1, Jae Myung Park1, Jong-Yul Lee1, Myong Ki Baeg1, Chul-Hyun Lim1, Jin Soo Kim1, Yu Kyung Cho1, In Seok Lee1, Sang Woo Kim1, Myung-Gyu Choi1.   

Abstract

AIM: To investigate whether proton pump inhibitor (PPI) pretreatment influences Helicobacter pylori eradication rate.
METHODS: We retrospectively reviewed H. pylori-infected patients who were treated with a standard triple regimen (PPI, amoxicillin 1 g, and clarithromycin 500 mg, all twice daily for 7 d). The diagnosis of H. pylori infection and its eradication was assessed with the rapid urease test, histological examination by silver staining, or the ¹³C-urea breath test. We divided the patients into two groups: one received the standard eradication regimen without PPI pretreatment (Group A), and the other received PPI pretreatment (Group B). The patients in Group B were reclassified into three groups based on the duration of PPI pretreatment: Group B-I (3-14 d), Group B-II (15-55 d), and Group B-III (≥ 56 d).
RESULTS: A total of 1090 patients were analyzed and the overall eradication rate was 80.9%. The cure rate in Group B (81.2%, 420/517) was not significantly different from that in Group A (79.2%, 454/573). The eradication rates in Group B-I, B-II and B-III were 80.1% (117/146), 81.8% (224/274) and 81.4% (79/97), respectively.
CONCLUSION: PPI pretreatment did not affect H. pylori eradication rate, regardless of the medication period.

Entities:  

Keywords:  Antibiotics; Drug resistance; Helicobacter pylori; Proton pump inhibitor; Urea breath test

Mesh:

Substances:

Year:  2014        PMID: 24574779      PMCID: PMC3921530          DOI: 10.3748/wjg.v20.i4.1061

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

1.  Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.

Authors:  Katsuyoshi Sugimoto; Tsukasa Uno; Hiroshi Yamazaki; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2008-01-30       Impact factor: 4.335

2.  The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection.

Authors:  P O Erah; A F Goddard; D A Barrett; P N Shaw; R C Spiller
Journal:  J Antimicrob Chemother       Date:  1997-01       Impact factor: 5.790

3.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

4.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

5.  Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers.

Authors:  N Bell; M D Karol; G Sachs; P Greski-Rose; D E Jennings; R H Hunt
Journal:  Aliment Pharmacol Ther       Date:  2001-01       Impact factor: 8.171

6.  Time to maximum effect of lansoprazole on gastric pH in normal male volunteers.

Authors:  N J Bell; R H Hunt
Journal:  Aliment Pharmacol Ther       Date:  1996-12       Impact factor: 8.171

7.  Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial.

Authors:  W L Peterson; D Y Graham; B Marshall; M J Blaser; R M Genta; P D Klein; C W Stratton; J Drnec; P Prokocimer; N Siepman
Journal:  Am J Gastroenterol       Date:  1993-11       Impact factor: 10.864

8.  Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori.

Authors:  J Labenz; E Gyenes; G H Rühl; G Börsch
Journal:  Am J Gastroenterol       Date:  1993-04       Impact factor: 10.864

9.  Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients.

Authors:  N Broutet; S Tchamgoué; E Pereira; H Lamouliatte; R Salamon; F Mégraud
Journal:  Aliment Pharmacol Ther       Date:  2003-01       Impact factor: 8.171

10.  Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers.

Authors:  E Bayerdörffer; S Miehlke; G A Mannes; A Sommer; W Höchter; J Weingart; W Heldwein; H Klann; T Simon; W Schmitt
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

View more
  8 in total

1.  The natural history of perforated foregut ulcers after repair by omental patching or primary closure.

Authors:  D Smith; M Roeser; J Naranjo; J A Carr
Journal:  Eur J Trauma Emerg Surg       Date:  2017-07-29       Impact factor: 3.693

Review 2.  Status of Epstein-Barr Virus Coinfection with Helicobacter pylori in Gastric Cancer.

Authors:  Shyam Singh; Hem Chandra Jha
Journal:  J Oncol       Date:  2017-03-21       Impact factor: 4.375

3.  Helicobacter pylori eradication in patients with type 2 diabetes mellitus: Multicenter prospective observational study.

Authors:  Seung-Joo Nam; Sung Chul Park; Sang Hoon Lee; Dong Wook Choi; Sung Joon Lee; Chang Seok Bang; Gwang Ho Baik; Jong Kyu Park
Journal:  SAGE Open Med       Date:  2019-02-19

Review 4.  When does proton pump inhibitor treatment become long term? A scoping review.

Authors:  Peter Fentz Haastrup; Dorte Ejg Jarbøl; Wade Thompson; Jane Møller Hansen; Jens Søndergaard; Sanne Rasmussen
Journal:  BMJ Open Gastroenterol       Date:  2021-02

5.  Detection of clarithromycin resistance and 23SrRNA point mutations in clinical isolates of Helicobacter pylori isolates: Phenotypic and molecular methods.

Authors:  Rawaa A Hussein; Mushtak T S Al-Ouqaili; Yasin H Majeed
Journal:  Saudi J Biol Sci       Date:  2021-09-16       Impact factor: 4.219

6.  Detection of Helicobacter Pylori infection by invasive and non-invasive techniques in patients with gastrointestinal diseases from Iraq: A validation study.

Authors:  Rawaa A Hussein; Mushtak T S Al-Ouqaili; Yasin H Majeed
Journal:  PLoS One       Date:  2021-08-23       Impact factor: 3.240

7.  The influence of pretreatment with PPI on Helicobacter pylori eradication: A systematic review and meta-analysis.

Authors:  Sheng Kuang; Jinkang Xu; Miaomiao Chen; Yongliang Zhang; Fangzhen Shi; Xirong Lu
Journal:  Medicine (Baltimore)       Date:  2021-11-24       Impact factor: 1.817

Review 8.  Clinical Factors Implicated in Antibiotic Resistance in Helicobacter pylori Patients.

Authors:  Brian White; Maria Winte; Joshua DeSipio; Sangita Phadtare
Journal:  Microorganisms       Date:  2022-01-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.